The global biomarkers market size is expected to reach over USD 129.4 billion by 2027, according to a new study conducted by Grand View Research Inc. It is anticipated to exhibiting a CAGR of 13.7%, during the forecast period. Factors, such as increasing collaborations and funds for R&D activities, rising consumer awareness, a widening patient base, and technological advancements collectively augmenting market growth.
The drug discovery segment
contributed the highest revenue in 2019. Pharmaceutical companies focus on
extensive R&D initiatives for the development of targeted therapeutics.
Coordinated strategic efforts on biomarker development remain a searing trend
among drug manufacturers, academic research institutions, commercial R&D
organizations, nonprofitable health foundations, and federal government
biomedical regulatory and research agencies.
North America continued to lead
the biomarkers market in 2019, driven by an amplifying demand for personalized
medicines, high disease prevalence, and proactive government initiatives. It is
expected to maintain its lead over the forecast period. Asia Pacific is
positioned to witness the fastest CAGR, over the forecast period, spearheaded
by India.
Some key market players include
Abbott; F. Hoffmann-La Roche Ltd.; Qiagen; Siemens Healthcare Private Limited;
Thermo Fisher Scientific, Inc.; Bio-Rad Laboratories, Inc.; Johnson &
Johnson Services, Inc; Agilent Technologies, Inc.; and Epigenomics AG. The
players are developing novel kits and therapies and drugs to target population
in the areas with high unmet clinical needs.
For Full Research Report On Biomarkers Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/biomarkers-industry
Further key
findings from the study suggest:
- Safety biomarkers captured
more than 41% market share in 2019, driven by increasing awareness
regarding routine healthcare checkups and reduction in drug attrition
- Validation biomarkers is
expected to demonstrate the fastest CAGR through to 2027
- Personalized medicine is
likely to expand at a CAGR of 14.8% over the forecast period due to
consumer awareness and preferences
- Cancer dominated the disease
segment in 2019, driven by a high disease burden and presence of a strong
pipeline
- Cardiovascular disease
segment is projected to witness the fastest growth in the forthcoming
years, supported by the growing obese population base and sedentary
lifestyles
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/biomarkers-industry/request/rs1
Grand View Research has segmented
the global biomarkers market on the basis of type, application, disease, and
region:
Biomarkers Type
Outlook (Revenue, USD Million, 2015 - 2027)
- Safety
- Efficacy
- Validation
Biomarkers
Application Outlook (Revenue, USD Million, 2015 - 2027)
- Diagnostics
- Drug Discovery &
Development
- Personalized Medicine
- Others
Biomarkers Disease
Outlook (Revenue, USD Million, 2015 - 2027)
- Cancer
- Cardiovascular Disease
- Neurological Disease
- Immunological Disease
- Others
Biomarkers Regional
Outlook (Revenue, USD Million, 2015 - 2027)
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Spain
- France
- Italy
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Latin America
- Brazil
- Mexico
- Argentina
- MEA
- South Africa
- Saudi Arabia
- UAE
About Grand View Research
Grand View Research, Inc. is a U.S. based
market research and consulting company, registered in the State of California
and headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment